Granulocyte Macrophage Colony Stimulating Factor GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500
Granulocyte Macrophage Colony Stimulating Factor GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2 Pipeline Review, H2 2017
Summary
Granulocyte Macrophage Colony Stimulating Factor GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2 pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report Granulocyte Macrophage Colony Stimulating Factor Pipeline Review, H2 2017, outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Granulocyte Macrophage Colony Stimulating Factor GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2 Granulocytemacrophage colonystimulating factor GMCSF is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts. It stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 3, 3 and 1 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System and Respiratory which include indications Breast Cancer, Rheumatoid Arthritis, Melanoma, Solid Tumor, Hepatocellular Carcinoma, Lymphoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Multiple Sclerosis, Muscle Invasive Bladder Cancer MIBC, Prostate Cancer, Renal Cell Carcinoma, Soft Tissue Sarcoma, Chronic Obstructive Pulmonary Disease COPD, Colon Carcinoma, Colorectal Cancer, Glioblastoma Multiforme GBM, Juvenile Myelomonocytic Leukemia JMML, Kidney Cancer Renal Cell Cancer, Leukemias, Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Lung Disease, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Liver Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Non Muscle Invasive Bladder Cancer NMIBC Superficial Bladder Cancer, Osteoarthritis Pain, Ovarian Cancer, Pancreatic Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma and Squamous Cell Carcinoma.
Furthermore, this report also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2
The report reviews Granulocyte Macrophage Colony Stimulating Factor GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2 targeted therapeutics and enlists all their major and minor projects
The report assesses Granulocyte Macrophage Colony Stimulating Factor GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
